This analysis suggested that intermediated traits such as obesity, the mammalian target of rapamycin, heme oxygenase-1 (an antioxidant with anti-inflammatory properties),28 and insulin are potential intermediate phenotypes that may inform the non-glycemic mediators of SGLT2 inhibitors on prostate cancer (Table S14). This evidence concerns the gene MTOR and prostate carcinoma.